Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
CEMI's Cash to Debt is ranked higher than
95% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. CEMI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CEMI' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 27.28 Max: No Debt
Current: No Debt
Equity to Asset 0.80
CEMI's Equity to Asset is ranked higher than
77% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. CEMI: 0.80 )
Ranked among companies with meaningful Equity to Asset only.
CEMI' s Equity to Asset Range Over the Past 10 Years
Min: -2.07  Med: 0.59 Max: 0.86
Current: 0.8
-2.07
0.86
F-Score: 3
Z-Score: 5.66
M-Score: -2.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -11.23
CEMI's Operating margin (%) is ranked lower than
56% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. CEMI: -11.23 )
Ranked among companies with meaningful Operating margin (%) only.
CEMI' s Operating margin (%) Range Over the Past 10 Years
Min: -83.68  Med: -1.66 Max: 15.41
Current: -11.23
-83.68
15.41
Net-margin (%) -8.33
CEMI's Net-margin (%) is ranked lower than
55% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. CEMI: -8.33 )
Ranked among companies with meaningful Net-margin (%) only.
CEMI' s Net-margin (%) Range Over the Past 10 Years
Min: -82.52  Med: -1.16 Max: 32.02
Current: -8.33
-82.52
32.02
ROE (%) -11.70
CEMI's ROE (%) is ranked lower than
55% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. CEMI: -11.70 )
Ranked among companies with meaningful ROE (%) only.
CEMI' s ROE (%) Range Over the Past 10 Years
Min: -14522.12  Med: 3.12 Max: 67.84
Current: -11.7
-14522.12
67.84
ROA (%) -9.40
CEMI's ROA (%) is ranked lower than
55% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. CEMI: -9.40 )
Ranked among companies with meaningful ROA (%) only.
CEMI' s ROA (%) Range Over the Past 10 Years
Min: -146.42  Med: -1.03 Max: 50.54
Current: -9.4
-146.42
50.54
ROC (Joel Greenblatt) (%) -26.14
CEMI's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. CEMI: -26.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CEMI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -597.6  Med: -1.05 Max: 98.41
Current: -26.14
-597.6
98.41
Revenue Growth (3Y)(%) 8.50
CEMI's Revenue Growth (3Y)(%) is ranked higher than
65% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. CEMI: 8.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CEMI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 3.90 Max: 59.1
Current: 8.5
0
59.1
» CEMI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CEMI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 222.22
CEMI's Forward P/E is ranked lower than
98% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.32 vs. CEMI: 222.22 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.46
CEMI's P/B is ranked higher than
55% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.84 vs. CEMI: 2.46 )
Ranked among companies with meaningful P/B only.
CEMI' s P/B Range Over the Past 10 Years
Min: 1.39  Med: 2.93 Max: 20.4
Current: 2.46
1.39
20.4
P/S 1.66
CEMI's P/S is ranked higher than
67% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. CEMI: 1.66 )
Ranked among companies with meaningful P/S only.
CEMI' s P/S Range Over the Past 10 Years
Min: 0.19  Med: 1.28 Max: 2.17
Current: 1.66
0.19
2.17
Current Ratio 3.32
CEMI's Current Ratio is ranked higher than
55% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. CEMI: 3.32 )
Ranked among companies with meaningful Current Ratio only.
CEMI' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 3.04 Max: 58
Current: 3.32
0.01
58
Quick Ratio 2.66
CEMI's Quick Ratio is ranked higher than
54% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. CEMI: 2.66 )
Ranked among companies with meaningful Quick Ratio only.
CEMI' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.34 Max: 58
Current: 2.66
0.01
58
Days Inventory 85.79
CEMI's Days Inventory is ranked higher than
53% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. CEMI: 85.79 )
Ranked among companies with meaningful Days Inventory only.
CEMI' s Days Inventory Range Over the Past 10 Years
Min: 58.96  Med: 73.57 Max: 87.12
Current: 85.79
58.96
87.12
Days Sales Outstanding 128.97
CEMI's Days Sales Outstanding is ranked lower than
88% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. CEMI: 128.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
CEMI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.72  Med: 62.72 Max: 116.23
Current: 128.97
26.72
116.23
Days Payable 32.65
CEMI's Days Payable is ranked lower than
73% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. CEMI: 32.65 )
Ranked among companies with meaningful Days Payable only.
CEMI' s Days Payable Range Over the Past 10 Years
Min: 32.15  Med: 42.94 Max: 206.77
Current: 32.65
32.15
206.77

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 4.54
CEMI's Price/Net Current Asset Value is ranked higher than
60% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.80 vs. CEMI: 4.54 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CEMI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.2  Med: 5.64 Max: 3853.33
Current: 4.54
2.2
3853.33
Price/Tangible Book 2.67
CEMI's Price/Tangible Book is ranked higher than
66% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.14 vs. CEMI: 2.67 )
Ranked among companies with meaningful Price/Tangible Book only.
CEMI' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.58  Med: 3.86 Max: 3425.19
Current: 2.67
1.58
3425.19
Price/Projected FCF 15.62
CEMI's Price/Projected FCF is ranked lower than
95% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. CEMI: 15.62 )
Ranked among companies with meaningful Price/Projected FCF only.
CEMI' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.49  Med: 4.03 Max: 14
Current: 15.62
1.49
14
Price/Median PS Value 1.40
CEMI's Price/Median PS Value is ranked lower than
83% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.91 vs. CEMI: 1.40 )
Ranked among companies with meaningful Price/Median PS Value only.
CEMI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 1.04 Max: 7.16
Current: 1.4
0.21
7.16
Earnings Yield (Greenblatt) (%) -6.86
CEMI's Earnings Yield (Greenblatt) (%) is ranked lower than
66% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. CEMI: -6.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CEMI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.6  Med: 4.35 Max: 11.3
Current: -6.86
0.6
11.3

More Statistics

Revenue(Mil) $27
EPS $ -0.24
Beta1.14
Short Percentage of Float0.09%
52-Week Range $3.33 - 5.53
Shares Outstanding(Mil)9.63

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 26 29 32 36
EPS($) -0.29 -0.30 -0.05 0.11
EPS without NRI($) -0.29 -0.30 -0.05 0.11

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, DGX, LIFE, ENZ, IDXX » details
Chembio Diagnostics Inc was formed in 1985. The Company with its subsidiaries develops, manufacture and market diagnostic tests that detect infectious diseases. The Company's main products presently commercially available are four rapid tests for the detection of HIV antibodies in whole blood, serum and plasma samples, all of which Employ lateral flow technology, and two of which were approved by the FDA in 2006. The Company's products are sold to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals and retail establishments both domestically and internationally. The Company's products are sold under its STAT PAK, SURE CHECK or DPP registered trademarks. The Company's HIV tests are qualitative (reactive/non-reactive) tests. Many of its competitors are substantially larger and have greater financial, research, manufacturing and marketing resources. The manufacturing and marketing of the Company's existing and proposed diagnostic products are regulated by the United States Food and Drug Administration ('FDA'), United States Department of Agriculture ('USDA'), certain state and local agencies, and/or comparable regulatory bodies in other countries.
» More Articles for CEMI

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
CEMI: Zika Could Be Seamless Fit to CEMI's Fever Portfolio Feb 02 2016
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 28 2016
Chembio to Sell Its SURE CHECK® HIV 1/2 Assay in the United States Beginning June 1, 2016 Jan 26 2016
Chembio to Sell Its SURE CHECK® HIV 1/2 Assay in the United States Beginning June 1, 2016 Jan 26 2016
Zacks SCR Analysts Attending JP Morgan Healthcare Conferences Jan 04 2016
Chembio Diagnostics, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 16 2015
CHEMBIO DIAGNOSTICS, INC. Financials Dec 08 2015
CEMI: Fever Portfolio Charging Out of the Gate Nov 13 2015
Chembio Diagnostics Reports Third Quarter Financial Results Nov 12 2015
Chembio Diagnostics Reports Third Quarter Financial Results Nov 12 2015
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Nov 12 2015
CHEMBIO DIAGNOSTICS, INC. Files SEC form 10-Q, Quarterly Report Nov 12 2015
Q3 2015 Chembio Diagnostics Inc Earnings Release - Before Market Open Nov 12 2015
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Nov 03 2015
Chembio to Commercialize Family of DPP® Malaria Assays Nov 03 2015
Chembio to Host Conference Call to Discuss Third Quarter 2015 Financial Results Nov 02 2015
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Oct 23 2015
Chembio Expands Point-of-Care Platform and Launches the DPP(R) Micro Reader Oct 21 2015
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Oct 09 2015
Chembio Diagnostics, Inc. Earnings Q2, 2015 Oct 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK